key: cord-0886594-8c5bnju7
authors: Navarro‐Millán, Iris; Sattui, Sebastian E.; Lakhanpal, Amit; Zisa, Diane; Siegel, Caroline H.; Crow, Mary K.
title: Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID‐19: A Case Series
date: 2020-06-30
journal: Arthritis Rheumatol
DOI: 10.1002/art.41422
sha: f981000b923965267e1dd7302ab9a90f69f1d0b9
doc_id: 886594
cord_uid: 8c5bnju7

OBJECTIVE: To report the clinical experience with anakinra for preventing mechanical ventilation (MV) in patients with COVID‐19, features of cytokine storm syndrome (CSS), and acute hypoxic respiratory failure (AHRF). METHODS: In this retrospective case series, patients must have had SARS‐CoV‐2, fever, ferritin >1,000 ng/mL with one additional laboratory marker of hyperinflammation, and AHRF. AHRF was defined as requiring 15L of supplemental oxygen via non‐rebreather mask combined with 6L nasal cannula or use of ≥95% oxygen by high flow nasal cannula. We excluded patients with suspicion for bacterial infection or on immunosuppressants. Subcutaneous anakinra was initiated at 100 mg q6 hours and gradually tapered off completely. Primary outcome was prevention of MV. RESULTS: Eleven of 14 patients meeting criteria received anakinra for a maximum of 19 days. Seven of those who initiated anakinra ≤36 hours after onset of AHRF did not require MV, and all were discharged home. Four patients who started anakinra ≥4 days after onset of AHRF required MV. Of those, 3 patients were extubated (2 discharged home, 1 remains hospitalized) and 1 died. All 3 patients who met criteria but did not receive anakinra required MV. Two were extubated (1 discharged and 1 remains hospitalized) and 1 remains on MV. CONCLUSIONS: Our data suggest that anakinra could be beneficial in COVID‐19 patients with evidence of CSS when initiated early after onset of AHRF. Our patient selection and treatment approach should be considered for investigation in a clinical trial to determine the safety and efficacy of anakinra in patients with COVID‐19 and features of CSS.

The clinical syndrome associated with infection from the severe acute respiratory syndrome coronavirus 2019 (SARS-CoV-2) is notable for its variability, ranging from asymptomatic infection to multi-organ failure and death. 1 In a study describing the first 393 patients with coronavirus disease at two New York City (NYC) hospitals, 77.1% had fever, a symptom driven by IL-1. 2 The clinical presentation, along with transcriptomic analysis of whole blood from COVID-19 patients demonstrating IL-1-alpha and IL-1-beta expression prior to the nadir of respiratory function, suggests that IL-1 may drive the pathophysiology of COVID-19. 3 Cytokine storm syndrome (CSS) has been observed in patients with COVID-19 and has been proposed to contribute to severe sequelae of disease such as acute hypoxic respiratory failure (AHRF) and death. 4 In distinct clinical settings, including macrophage activation syndrome (MAS), elevated levels of pro-inflammatory cytokines and other laboratory indicators, including ferritin, Creactive protein (CRP), D-dimer, and lymphopenia, have been observed. 5 In the context of systemic juvenile idiopathic arthritis (SJIA), the prototypic disease for such syndromes, controlled clinical trials of an IL-1 inhibitor clearly demonstrated safety and efficacy. 6 Based on the experience of clinicians, and particularly rheumatologists, IL-1 inhibition has been used in additional rare syndromes characterized by induction of hyperinflammation mediated by impaired regulation of the cytokine response. 7, 8 Anakinra, a recombinant IL-1 receptor antagonist approved by the Food and Drug Administration for use in Neonatal-Onset Multisystem Inflammatory Disease and rheumatoid arthritis, inhibits both IL-1-alpha and IL-1-beta. Because it inhibits both IL-1 subtypes and has a short half life, anakinra could be a promising treatment for patients with severe COVID-19. The objective of this study was to report a single-center preliminary experience using anakinra as part of clinical care to prevent progression to mechanical ventilation (MV) in patients with COVID-19 presenting with clinical and laboratory evidence of CSS and AHRF.

This was a retrospective case series of patients with COVID-19, AHRF, and signs and symptoms of CSS. We evaluated patients with COVID-19 through the rheumatology inpatient consult service at New York Presbyterian Hospital (NYP)-Weill Cornell Medicine and NYP-Lower Manhattan

This article is protected by copyright. All rights reserved Hospital from April 1 through June 2, 2020. Supplemental Table 1 presents detailed inclusion and exclusion criteria used to guide the use of anakinra to treat CSS in patients with COVID-19. In summary, we required that patients have molecular documentation of SARS-CoV-2, fever (documented or historical), ferritin >1,000 ng/mL with one additional laboratory marker of hyperinflammation, and AHRF. AHRF was defined as requiring either 15 liters (L) of supplemental oxygen (O 2 ) via non-rebreather (NRB) mask combined with 6L nasal cannula (NC) or ≥95% oxygen by high flow nasal cannula (HFNC). Patients on invasive MV at the time of evaluation were ineligible.

Patients were considered for treatment with anakinra only after they were deemed ineligible for any ongoing clinical trial for patients with COVID-19. We obtained and documented verbal consent for the off-label use of anakinra in these patients. The Weill Cornell Medicine Institutional Review Board approved this study.

Only subcutaneous (SQ) anakinra was available at our institution's pharmacy. Patients were started on anakinra 100 mg SQ every 6 hours; however, while a uniform treatment plan and secure supply of medication was being established, the first two patients were treated initially with doses below the proposed 100 mg every 6 hours. The dosing frequency of anakinra was gradually decreased to every 8, 12, and 24 hours, over a maximum treatment duration of 20 days. We tapered anakinra based on decreasing oxygen requirement and clinical improvement, or in response to elevated transaminases, cytopenias, concern for new bacterial infection (based on positive cultures, increase in procalcitonin to >0.6 ng/mL, or high clinical suspicion), or worsening renal function. We continued anakinra in patients requiring MV with the goal that its use could facilitate extubation.

There were three patients who met our eligibility criteria but were not given anakinra because it was unavailable or the patient declined it. We considered continuing anakinra after discharge from the hospital based on clinical response and tolerability; in most cases we discontinued it because patients had improved significantly by that time and the likelihood of further decompensation was low.

We allowed background methylprednisolone, empiric antibiotics and hydroxychloroquine, which were included in the clinical care protocols for COVID-19 at NYP. Several patients received anakinra together with methylprednisolone, as this was being considered for all patients with Accepted Article worsening respiratory failure at high risk for MV at our institution. None of these patients received remdesivir. We excluded patients with cancer receiving chemotherapy or immunotherapy and patients on other immunosuppressive biologics. Supplemental Table 1 provides details regarding exclusion criteria.

We monitored vital signs, oxygen requirement, ferritin level, complete blood count with differential, comprehensive metabolic panel, erythrocyte sedimentation rate, CRP, lactate dehydrogenase, international normalized ratio, and prothrombin time.

The primary outcome was prevention of MV. Clinical response was defined as the patient being weaned off O 2 or to 2L O 2 by NC. Failure to respond was defined as requiring MV. We used the ordinal scale of the World Health Organization trials for COVID-19 (Supplemental Table 2 ) to measure respiratory outcomes. 9 The maximum duration of treatment with anakinra was 20 days. We followed the patients until they were able to wean off O 2 or until discharge.

Fourteen patients met our criteria for CSS in the setting of severe COVID-19 pneumonia and AHRF (Table 1) . Eleven received anakinra. The initial dose of anakinra was lower for the first 2 patients treated; once we established a treatment guideline and had adequate supply of the medication the remaining patients were treated in a standardized way. The majority of the patients that did not meet our AHRF definition had a less severe form of COVID-19 and improved gradually over time on their own (data not shown). Table 2 shows the doses of anakinra and background medications that each patient received including the dosage and duration of methylprednisolone. Patients treated with anakinra within 36 hours of meeting our O 2 supplementation threshold for eligibility (early-initiation) did not require MV (patients 1-3, 6, 8, 11) or avoided recurrent MV (patient 9). All patients not requiring MV were discharged home. Patients whose O 2 requirements met our AHRF definition for 4 or more days prior to initiating anakinra (late-initiation) required MV (patients 4, 5, 7, 10). We continued anakinra in all late-initiation patients to facilitate extubation. Two patients developed infections (patients 4 and 7)

prompting discontinuation of anakinra. Three of the 4 late-initiation patients were extubated and 2

were discharged home (patients 7 and 10). One remains in the hospital (patient 4). For those intubated, the duration of MV ranged from 7 to 19 days. For patient 5, anakinra was initiated before blood culture results were available; once a bacterial infection was identified, anakinra was discontinued, but the patient died weeks later. Three of the 14 patients meeting criteria did not receive anakinra (patients 12-14); all required MV and then received an IL-6 antagonist (after documentation of elevated IL-6). IL-6 levels were elevated only in these 3 patients; 1 was extubated and discharged home (patient 13) and 2 remain in the hospital, 1 still intubated (patient 14) and the other initially failed extubation but was successfully extubated 7 days later (patient 12) ( Table 2 ).

All eligible patients had ferritin levels over 1,000 ng/mL for 1 to 2 days before consultation ( Figure 1A ). Ferritin levels trended down, but only 2 patients achieved levels below 500 ng/mL by the study's conclusion. Most of the patients also had lymphocyte counts less than 1,200/uL at the time of consultation, and 5 had lymphocyte counts greater than 1,500/uL by the end of follow up ( Figure 1B ).

Nearly all patients had a CRP greater than 5 mg/dL, which trended down or normalized in all but one patient who developed a superimposed infection ( Figure 1C ). In patients 12-14, the levels of ferritin and lymphocyte counts were similar to those of the patients that received anakinra and did not fluctuate over the course of the disease and our observation period; CRP levels normalized within 2 days of receiving anti-IL-6 biologic (data not shown).

This case series suggests that anakinra confers the greatest benefit in COVID-19 with features of CSS when patients require high levels of supplemental O 2 for <2 days and before intubation. Our treatment strategy involved giving high doses of anakinra soon after development of AHRF followed by a slow tapering over a maximum of 20 days, guided by clinical response and tolerability. The goal of treating patients at risk for MV was to prevent organ damage, morbidity and, in the setting of a rapidly progressing pandemic, depletion of healthcare resources such as ventilators. Our data demonstrate that the early-initiation patients did not require MV and have been discharged home. This early aggressive treatment was likely key in improving the patients' risk for requiring MV without major risk of complications. For patients requiring MV, anakinra should be used with caution due to risk of complications such as superimposed bacterial infection.

To date, there are several reports from Europe regarding the use of anakinra in patients with COVID-19. Unlike our study, they did not require that patients have severe respiratory failure in order to initiate anakinra. [10] [11] [12] Such an approach increases the possibility of overestimating the medication's Accepted Article efficacy and confers potentially unnecessary risk of medication side effects. Our criteria for initiating anakinra included severe respiratory failure to avoid treating patients who are more likely to improve without immunosuppression. We defined a specific phenotype of patients with COVID-19, which allowed us to examine the clinical response in a group of patients with similar clinical presentation.

Three of the patients who fit this phenotype did not receive anakinra and instead received an IL-6 antagonist after documentation of elevated IL-6. Two were successfully extubated. Since IL-1 can induce IL-6, it is possible that anakinra could have prevented MV in those 3 patients. The possibility that anakinra may have improved outcomes in those patients is also supported by the presence of fever, a symptom mediated by IL-1. 13 MV is a known risk factor for developing bacterial pneumonia. Both patients who continued anakinra after requiring MV developed superimposed bacterial infection, which suggests anakinra may have augmented this risk. However, for patients who did not require MV, anakinra was well tolerated without development of major infections. Elevation in transaminase levels was the most frequently observed laboratory abnormality patients developed on anakinra. It is possible that these changes were caused by CSS itself; in all cases, the enzyme levels improved after lowering the anakinra dose, so discontinuation was not necessary. All patients were able to tolerate between 2 to 6 days of anakinra 100 mg every 6 hours before we decided to lower the dose. The most common reasons for decreasing the dose were clinical improvement or elevation in transaminase levels. Only Accepted Article one individual on anakinra experienced an injection site reaction, and this was the patient with the longest duration of treatment (19 days). Some studies of MAS used intravenous (IV) anakinra while our study used the SQ form. 11 The pharmacokinetics of the medication could be affected by SQ administration leading to slowed absorption, especially in obese patients. Still, our study provides insight into the use of SQ anakinra when the IV form is not available.

Our study is the first report from the U.S. to examine the use of anakinra in patients with COVID-19 and features of CSS. A strength of our study is that we defined a narrow phenotype, which enabled us both to target a specific group of patients most likely to benefit from anakinra and to avoid risks of immunosuppression in patients more likely to recover on their own. Whereas previous studies in MAS used primarily intravenous (IV) anakinra, our study showed benefit with SQ anakinra. Our study has several limitations, including a small sample and the absence of controls.

We were still able to examine the relevance of our selection criteria by documenting clinical progression of 3 patients who did not receive the anakinra.

Our experience provides insight regarding the use of anakinra in COVID-19 patients with severe AHRF and features of CSS. We identified a specific patient phenotype with COVID-19 that might benefit most from treatment with anakinra. It also provides guidance on a treatment strategy that employs high doses of anakinra for a minimum of 3 to 4 days followed by a slow taper based on clinical response and side effects, such as elevation in transaminases. The results of this study suggest that anakinra should be used cautiously in patients requiring MV, as those patients 

This article is protected by copyright. All rights reserved (6) 41 days on MV as of June 2, 2020.

All except patients 8 and 11 received hydroxychloroquine. All patients were off anakinra by the end of the case series.

*Patient's blood culture were drawn before anakinra was initiated and results were pending when the medication was started. Once the results were positive, we discontinued anakinra. Ɨ Clinical status graded on 9-point ordinal scale suggested by the World Health Organization.

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical Characteristics of Covid-19 in New York City

A Dynamic Immune Response Shapes COVID-19

Cell host & microbe

COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet

Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis

A multicentre, randomised, double-blind, placebocontrolled trial with the interleukin-1 receptor antagonist anakinra in patients with systemiconset juvenile idiopathic arthritis (ANAJIS trial)

Anakinra Therapy for Non-cancer Inflammatory Diseases

Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome

Coronavirus disease (COVID-19) Therapeutic Trial Synopsis

Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series. Annals of the Rheumatic Diseases

Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease. The Journal of allergy and clinical immunology

Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. The Lancet Rheumatology

The history of fever, leukocytic pyrogen and interleukin-1. Temperature (Austin)

Age adjusted rates of laboratory confirmed COVID-19 non-hospitalized cases, estimated non fatal hospitalized cases, and patients known to have died 100,000 by race/ethnicity group as of

Whole-Exome Sequencing Reveals Mutations in Genes Linked to Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome in Fatal Cases of H1N1 Influenza